武田制药 TAK 深沪

等待开盘 05-18 09:30:00 美东时间

16.61

-0.020

-0.12%

华盛通

立即下载

最高16.73
今开16.69
成交量 278.91万股
最低 16.59
昨收 16.63
总市值 5248.22万
52周最高 18.895
市盈率 ^静 41.84
换手率 0.01%
52周最低 12.6916
委比 47.88%
总股本 0.03亿
历史最高 18.895
量比 0.65
振幅 0.84%
历史最低 8.492
每手 1
风险率 1.65%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Takeda to shed 4,500 jobs as part of cost-cutting drive

Takeda Pharmaceutical (TAK) has announced that it will eliminate nearly 4,500 roles globally in fiscal 2026 as part of a restructuring drive expected to generate as much as ¥200B ($1.3B) in annualized...

05-14 22:37
武田制药大裁员4500人！新CEO接棒，押注三款First-in-class新药开启增长新时代

（来源：抗体圈） 5月13日，日本制药巨头武田制药（TSE:4502/NYSE:TAK）同步发布 2025 财年（截至 2026 年 3 月 31 日）全年...

05-14 11:45
Takeda's Next Wave Of Drugs Has Investors Watching Closely

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK's late-stage pipeline and 2026 forecasts.

05-13 23:38
Earnings Scheduled For May 13, 2026

Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...

05-13 19:11
Takeda Pharmaceutical Co Sees FY2026 GAAP EPS $0.66.

Takeda Pharmaceutical Co (NYSE:TAK) is looking for FY2026 GAAP EPS of $0.66.

05-13 19:00
Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.21 by 33.33 percent. This is a 75 percent increase over earnings of $0.16 per share from the

05-13 16:47
武田制药(TAK)2025财年核心每股收益达517日元同比增长5.2%

金吾资讯

05-13 16:26
擎启新程沃赢未来丨九州通全擎健康×武田制药沃克零售CSO项目正式启航！

5月11日，九州通医药集团旗下产品CSO专业子集团——全擎健康，与全球领先的生物制药企业武田制药在武汉隆重举行项目启动会，双方就沃克（富马酸伏诺拉生片）达成C...

05-12 18:28
Takeda Announces That The TAK-881-300 Phase 2/3 Clinical Trial In Patients With Primary Immunodeficiency Disease 1 Met Its Primary Endpoint,

TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational

05-04 20:02
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding its use beyond depression in a large market.

05-01 20:49

派息除权日	每股总股息	派息日期
2026-03-31	0.30
2025-09-30	0.32
2025-03-31	0.32
2024-09-30	0.33	2024-09-30
2024-03-27	0.30	2024-03-27
2023-09-28	0.26	2023-12-11
2023-03-30	0.27	2023-07-10
2022-09-29	0.30	2022-09-29
2022-03-30	0.36	2022-03-30
2021-09-29	0.39	2021-09-29
2021-03-30	0.40	2021-03-30
2020-09-29	0.37	2020-09-29
2020-03-30	0.32	2020-07-06
2019-09-27	0.32	2019-12-12
2019-03-27	0.36	2019-06-28
2018-09-26	0.30	2018-12-01
2018-03-27	0.30	2018-07-09
2017-09-27	0.31	2017-12-01
2017-03-29	0.36	2017-07-10
2016-09-28	0.29	2016-12-12
2016-03-29	0.32	2016-07-11
2015-09-28	0.28	2015-12-11
2015-03-27	0.33	2015-06-01
2014-09-26	0.29	2014-12-11
2014-03-27	0.37	2014-06-30
2013-09-26	0.43	2013-12-01
2013-03-27	0.45	2013-06-01
2012-09-26	0.55	2012-09-26
2012-03-28	0.50	2012-07-09
2011-09-28	0.51	2011-12-12
2011-03-29	0.49	2011-07-07
2010-09-27	0.50	2010-12-13
2010-03-29	0.45	2010-07-14
2009-09-25	0.46	2009-12-15
2009-03-26	0.42	2009-07-14
2008-09-25	0.41	2008-12-16
2008-03-26	0.36	2008-03-26

公司名称	Takeda Pharmaceutical Co., Ltd.
行业分类	Pharmaceuticals: Major
业务描述	Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

武田制药 TAK 深 沪

16.61

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

武田制药 TAK 深沪